-
公开(公告)号:US11866428B2
公开(公告)日:2024-01-09
申请号:US17034926
申请日:2020-09-28
发明人: Alison Jo-Anne Woolford , Steven Howard , Ildiko Maria Buck , Gianni Chessari , Christopher Norbert Johnson , Emiliano Tamanini , James Edward Harvey Day , Elisabetta Chiarparin , Thomas Daniel Heightman , Martyn Frederickson , Charlotte Mary Griffiths-Jones
IPC分类号: C07D471/04 , C07D401/06 , C07D471/10 , C07D403/06 , C07D487/10 , C07D403/14 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/5377 , C07D413/14 , C07D487/04 , C07D519/00
CPC分类号: C07D471/04 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5025 , A61K31/5377 , C07D401/06 , C07D403/06 , C07D403/14 , C07D413/14 , C07D471/10 , C07D487/04 , C07D487/10 , C07D519/00
摘要: The invention relates to bicyclic heterocycle compounds of formula (I):
or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.-
公开(公告)号:US20130210820A1
公开(公告)日:2013-08-15
申请号:US13753904
申请日:2013-01-30
IPC分类号: C07D295/155
CPC分类号: C07D295/155 , C07D209/44
摘要: The invention provides a compound of the formula (1): or a salt, solvate, N-oxide or tautomer thereof.
摘要翻译: 本发明提供式(1)化合物或其盐,溶剂化物,N-氧化物或其互变异构体。
-
公开(公告)号:US09676768B2
公开(公告)日:2017-06-13
申请号:US14663534
申请日:2015-03-20
发明人: Alison Jo-Anne Woolford , Steven Howard , Ildiko Maria Buck , Gianni Chessari , Christopher Norbert Johnson , Emiliano Tamanini , James Edward Harvey Day , Elisabetta Chiarparin , Thomas Daniel Heightman , Martyn Frederickson , Charlotte Mary Griffiths-Jones
IPC分类号: A61K31/497 , A61K31/501 , C07D403/04 , C07D419/00 , C07D471/04 , C07D401/06 , C07D471/10 , C07D403/06 , C07D487/10 , C07D403/14 , A61K31/496 , A61K31/5025 , A61K31/506 , A61K31/5377 , C07D413/14 , C07D487/04 , C07D519/00
CPC分类号: C07D471/04 , A61K31/496 , A61K31/497 , A61K31/501 , A61K31/5025 , A61K31/506 , A61K31/5377 , C07D401/06 , C07D403/06 , C07D403/14 , C07D413/14 , C07D471/10 , C07D487/04 , C07D487/10 , C07D519/00
摘要: The invention relates to bicyclic heterocycle compounds of formula (I): or tautomeric or stereochemically isomeric forms, N-oxides, pharmaceutically acceptable salts or the solvates thereof; wherein R1, R2a, R2b, R3a, R3b, R5, R6, R7, R8, R9, p and E are as defined herein; to pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
-
4.
公开(公告)号:US20150045362A1
公开(公告)日:2015-02-12
申请号:US14467946
申请日:2014-08-25
发明人: Gianni Chessari , Miles Stuart Congreve , Martyn Frederickson , Christopher William Murray , Eva Figueroa Navarro , Alison Jo-Anne Woolford
IPC分类号: C07D401/12 , C07C65/21 , C07D401/04 , C07D209/44
CPC分类号: C07D401/12 , C07C65/21 , C07D209/08 , C07D209/44 , C07D215/08 , C07D217/06 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/04 , C07D413/04 , C07D413/06 , C07D413/12 , C07D413/14 , C07D471/04 , C07D471/10 , C07D491/08 , C07D491/10
摘要: The invention provides compounds of the formula (I): or salts, tautomers, solvates and N-oxides thereof; wherein R1 is hydroxy or hydrogen; R2 is hydroxy; methoxy or hydrogen; provided that at least one of R1 and R2 is hydroxy; R3 is selected from hydrogen; halogen; cyano; optionally substituted C1-5 hydrocarbyl and optionally substituted C1-5 hydrocarbyloxy; R4 is selected from hydrogen; a group —(O)n—R7 where n is 0 or 1 and R7 is an optionally substituted acyclic C1-5 hydrocarbyl group or a monocyclic carbocyclic or heterocyclic group having 3 to 7 ring members; halogen; cyano; hydroxy; amino; and optionally substituted mono- or di-C1-5 hydrocarbyl-amino; or R3 and R4 together form a monocyclic carbocyclic or heterocyclic ring of 5 to 7 ring members; and NR5R6 forms an optionally substituted bicyclic heterocyclic group having 8 to 12 ring members of which up to 5 ring members are heteroatoms selected from oxygen, nitrogen and sulphur.The compounds have activity as Hsp90 inhibitors.
摘要翻译: 本发明提供式(I)的化合物:或其盐,互变异构体,溶剂合物和N-氧化物; 其中R1是羟基或氢; R2是羟基; 甲氧基或氢; 条件是R 1和R 2中的至少一个是羟基; R3选自氢; 卤素; 氰基; 任选取代的C 1-5烃基和任选取代的C 1-5烃氧基; R4选自氢; 其中n为0或1,R7为任选取代的无环C 1-5烃基或具有3至7个环成员的单环碳环或杂环基团 - (O)n -R 7基团; 卤素; 氰基; 羟基; 氨基; 和任选取代的单或二-C 1-5烃基 - 氨基; 或R 3和R 4一起形成5至7个环成员的单环碳环或杂环; 并且NR 5 R 6形成具有8至12个环成员的任选取代的双环杂环基,其中多达5个环成员是选自氧,氮和硫的杂原子。 该化合物具有作为Hsp90抑制剂的活性。
-
公开(公告)号:US08664218B2
公开(公告)日:2014-03-04
申请号:US13753904
申请日:2013-01-30
IPC分类号: A61K31/5377 , C07D209/44
CPC分类号: C07D295/155 , C07D209/44
摘要: The invention provides a compound of the formula (1): or a salt, solvate, N-oxide or tautomer thereof.
摘要翻译: 本发明提供式(1)化合物或其盐,溶剂化物,N-氧化物或其互变异构体。
-
-
-
-